Metformin attenuates the systemic biological effect of IR/IGF on tumor-promoting signaling by improving insulin sensitivity and suppressing liver glucose output, which leads to reduced levels of systemic circulating insulin [14]. This evidence concerns the gene INS and neoplasm.